News & Events
For media inquiries email [email protected]
Company news
November 21, 2025
Press Release
Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
Publications and presentations
November 21, 2025
SNO Annual Meeting
A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor – Safety and preliminary antitumor activity in patients with adamantinomatous craniopharyngioma
November 13, 2025
CTOS Annual Meeting
A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor – Safety and preliminary antitumor activity in patients with desmoid tumors
October 25, 2025
PCF Scientific Retreat
Discovery and Optimization of ERG Bifunctional, Stapled Peptide Degraders using Generative AI–Driven Multi-Property Modeling
Recent highlights
October 7, 2025
Panel
“Fierce 15 – Where are they now?” Panel at Fierce Biotech Week
Parabilis Chief Business Officer Greg Miller joined the “Fierce 15 – Where are they now?” panel at Fierce Biotech Week – a check in with leaders from companies previously recognized by Fierce as the most promising emerging biotechs pushing the boundaries of science. During the panel, Greg and fellow life science leaders explored topics including partnerships and how companies are building their business models in today’s market. The panel was recorded and published on Fierce’s “The Top Line” podcast.